Eleven Biotherapeutics (NASDAQ:EBIO) has climbed 24.6% in the past week and advanced 109.91% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 26.09% and the outperformance has advanced to 107.99% for the last 4 weeks period.
Eleven Biotherapeutics (NASDAQ:EBIO): The stock opened at $2.60 on Friday but the bulls could not build on the opening and the stock topped out at $2.62 for the day. The stock traded down to $2.27 during the day, due to lack of any buying support eventually closed down at $2.33 with a loss of -9.34% for the day. The stock had closed at $2.57 on the previous day. The total traded volume was 2,294,518 shares.
The company shares have dropped -15.88% from its 1 Year high price. On Aug 12, 2015, the shares registered one year high at $8.00 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $1.43 and the 200 Day Moving Average price is recorded at $1.22.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Mccabe John J, officer (Senior Vice President, Finance) of Eleven Biotherapeutics, Inc., had unloaded 1,501 shares at an average price of $0.27 in a transaction dated on February 16, 2016. The total value of the transaction was worth $405.
Many analysts have stated their opinion on the company shares. Citigroup maintains its view on Eleven Biotherapeutics (NASDAQ:EBIO) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Citigroup lowers the price target from $1 per share to $0.4 per share on Eleven Biotherapeutics . The rating by the firm was issued on March 16, 2016. Currently the company Insiders own 28.9% of Eleven Biotherapeutics shares according to the proxy statements. Institutional Investors own 26.29% of Eleven Biotherapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -3.94%.
Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye. The Company is conducting research and development programs directed at both diseases of the front of the eye, such as dry eye disease and allergic conjunctivitis, and diseases of the back of the eye, such as diabetic macular edema (DME) and uveitis. The Companys lead product candidate is EBI-005, a cure for dry eye disease and allergic conjunctivitis. Its preclinical product candidates include EBI-031, a cure for DME, and EBI-028, a cure for uveitis.